Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ori CAR 001

Drug Profile

Ori CAR 001

Alternative Names: Anti-GPC3 CAR-T cell therapy - OriginCell Therapeutics; G3-CAR-Ori2; Ori-C101; Ori-CAR-001; OriC101 - OriCell Therapeutics

Latest Information Update: 02 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OriginCell Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Liver cancer

Most Recent Events

  • 15 Dec 2022 Phase-I/II clinical trials in Liver cancer (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in China (IV) (NCT05652920)
  • 21 Sep 2022 The National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) submission for Ori C101 for the treatment of Liver cancer
  • 06 Jun 2021 Preliminary efficacy and adverse events data from phase I trial in Liver cancer released by OriginCell Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top